esmo.org - pannes et problèmes

Qu'est-il arrivé à esmo.org, pourquoi le site Web est-il tombé en panne et n'a-t-il pas fonctionné? Ici, vous pouvez voir qui d'autre a le même problème avec esmo.org, ainsi que des solutions possibles. Selon nos statistiques, les suivantes ne fonctionnent le plus souvent: .

Statut actuel: Aucun échec

Pour le moment, selon nos données, esmo.org fonctionne correctement, mais des échecs uniques sont possibles. Si esmo.org ne fonctionne pas pour vous, signalez votre problème et écrivez un commentaire.
Ajouter un commentaire

Que faire si le site esmo.org n'est pas disponible? Essayez notre guide.

esmo.org - rapports de panne au cours des dernières 24 heures

esmo.org - rapports d'erreurs et d'échecs, méthodes de dépannage

Laissez votre commentaire décrivant l'échec et partagez avec les autres utilisateurs comment résoudre le problème.
  • Aucune inscription requise.
  • Les messages contenant un langage obscène et des insultes, ainsi que la violation de la loi, ne sont pas autorisés à être publiés.
  • Liens actifs dans le texte du message n'est pas publié, mais affiché en clair.
  • Il est interdit de publier vos propres données personnelles et celles d'autres personnes: adresses, numéros de téléphone, e-mails, comptes dans des messageries instantanées, etc.

Informations techniques

Titre de la page principale:
European Society for Medical Oncology
Description de la page principale:
ESMO is the European Society for Medical Oncology, providing a professional network for its members and working with national societies across Europe.
Mots clés de la page principale:
medical oncology,oncologists,oncology societies,oncology conferences,europe
Protocole:
https
Code de statut :
200
Taille de la page:
344.0 Ko
Délai de réponse:
0.236sec.
IP:
3.74.48.128
En-têtes de réponse:
content-type: text/html; charset=UTF-8
date: Wed, 02 Oct 2024 04:15:31 GMT
x-varnish: 329838340 329511141
age: 7762
vary: Accept-Encoding
cache-control: private, no-cache, no-store, must-revalidate
accept-ranges: bytes
transfer-encoding: chunked
strict-transport-security: max-age=16000000; preload;
connection: close
Enregistrements DNS:
A address3.74.48.128
ttl3600
MX exchangeesmo-org.mail.protection.outlook.com
priority1
NS valuens-962.awsdns-56.net
NS valuens-160.awsdns-20.com
NS valuens-1381.awsdns-44.org
NS valuens-1950.awsdns-51.co.uk
TXT entries_globalsign-domain-verification=LOWe8o5b8M5jF91_NdqFCcp55JzNqaG9vaYxpU1A2p
TXT entries1 esmo-org.mail.protection.outlook.com
TXT entriesv=spf1 include:spf.protection.outlook.com include:_spf.salesforce.com include:sendgrid.net include:mailsenders.netsuite.com include:363969.spf01.hubspotemail.net ip4:149.72.162.194 ip4:20.197.83.124 ip4:52.58.107.253 -all
TXT entriesasv=87683baf2eccb6ea11de30fecbfdea3d
TXT entriesatlassian-domain-verification=P6cV979MoWf4HJCNatgyqRkUosrd0zlhDuo1PjEZmh0dHEaNdn0GtI7K/2WzRNpJ
TXT entriesgoogle-site-verification=LBG3j6v_Zp339Qqc1kuH0CTsCp65geAzIBw07pOBWOw
SOA nsnamens-962.awsdns-56.net
hostmasterawsdns-hostmaster.amazon.com
serial1
refresh7200
retry900
expire1209600
minttl86400

En-têtes SEO

h1 European Society For Medical Oncology
h2 ESMO Immuno-Oncology Congress 2024
h2 Metastatic Triple Negative Breast Cancer
h2 Late Stage Ovarian Cancer Webinar
h2 RWD Reporting and Interpretation
h2 October ESMO Virtual Journal Club
h2 Molecular Analysis for Precision Oncology Congress 2024
h2 ESMO Targeted Anticancer Therapies Congress 2025
h2 The ESMO Living Guideline on Metastatic Colorectal Cancer is updated!
h2 ESMO Breast Cancer 2025
h2 ESMO-MCBS
h2 Latest News
h2 Off-label use of cancer medicines: an option not without challenges
h2 How to bridge the gap between palliative care and oncology?
h2 Frontline abemaciclib plus endocrine therapy showed superior efficacy compared to chemotherapy in aggressive HR+/HER2– breast cancer
h2 Promising antitumour activity presented for emerging targets in different solid tumours
h2 Physical activity is beneficial for patients with cancer, but also challenging
h2 Some clinical activity was reported for novel tyrosine kinase inhibitors in previously treated patients with GIST
h2 Alectinib shows benefit across genetic profiles in resected ALK-positive NSCLC
h2 Regorafenib delays disease progression in patients with soft tissue sarcoma
h2 Rising rates of cancer in young people: nature or nurture?
h2 Rare Endocrine Tumours: ESMO Clinical Practice Guideline
h2 Adjuvant Pembrolizumab Plus Chemotherapy Improves DFS in Patients with Newly-Diagnosed, High-Risk dMMR Endometrial Cancer, but Not in All-Comer Population
h2 Off-label use of cancer medicines: an option not without challenges
h2 Patient Guide in Oesophageal Cancer Now Available Also in Greek
h2 EMA Recommends Granting a Marketing Authorisation for Mirvetuximab Soravtansine
h2 How to bridge the gap between palliative care and oncology?
h2 Substantial and Durable Overall and Intracranial Activity of Trastuzumab Deruxtecan in Previously Treated HER2-positive mBC Including a Large Cohort of Patients with Brain Metastases
h2 Ahead of the Publication of the Heitor Report, ESMO Calls for Cancer Research to Be Prioritised Under the EU’s 10th Framework Programme
h2 No Survival Benefit from Adding Preoperative Chemoradiotherapy to Perioperative Chemotherapy in Patients with Resectable Gastric/GEJ Adenocarcinoma
h2 Adjuvant Pembrolizumab Plus Chemotherapy Improves DFS in Patients with Newly-Diagnosed, High-Risk dMMR Endometrial Cancer, but Not in All-Comer Population
h2 EMA Recommends Granting a Marketing Authorisation for Mirvetuximab Soravtansine
h2 Substantial and Durable Overall and Intracranial Activity of Trastuzumab Deruxtecan in Previously Treated HER2-positive mBC Including a Large Cohort of Patients with Brain Metastases
h2 No Survival Benefit from Adding Preoperative Chemoradiotherapy to Perioperative Chemotherapy in Patients with Resectable Gastric/GEJ Adenocarcinoma
h2 Adjuvant Pembrolizumab Prolongs DFS Among Patients with High-Risk Muscle Invasive Urothelial Carcinoma
h2 FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for NSCLC with EGFR Exon 19 Deletions or L858R Mutations
h2 177Lu-PSMA-617 Prolongs rPFS Relative to Androgen Receptor Pathway Inhibitor Change, with a Favourable Safety Profile in Patients with PSMA-positive mCRPC
h2 Inhibition of GDF-15 with Ponsegromab Results in Increased Weight Gain and Overall Activity Level and Reduced Cancer Cachexia Symptoms
h2 FDA Approves Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
h2 Studies Show Immunotherapy Improves Long-Term Survival in Growing Number of Cancers
h2 Gynaecological Cancers: Immunotherapy and Novel Targeted Drug Appear Beneficial in Group of Women with Early-Stage Disease
h2 From Practice-Changing Data to Future Innovation, Patient Outcomes to Doctors’ Wellbeing, the ESMO Congress 2024 Takes a Holistic View of Oncology
h2 ESMO 2024 Press Conference
h2 ESMO Calls for Concerted Action to Prevent Burnout and Foster Well-Being within the Oncology Workforce
h2 Studies Provide First Evidence That Breastfeeding after Breast Cancer Is Safe
h2 ESMO Congress 2024 Barcelona, Spain, 13-17 September
h2 Prevention and Early Detection of Gastrointestinal Cancers Take on New Importance Amidst a Younger Population
h2 Cross-Border Network of European Specialists Provides New Treatment Options For Women with Complex Rare Gynaecological Cancers
h2 ESMO Congress 2024: Five Days of Science Dissemination and Education
h2 2024 ESMO Fellowship Awardees Announced
h2 ESMO Releases a New Framework to Assess the Tumour-Agnostic Potential of Cancer Therapies
h2 Recipients of the 2024 ESMO Society Awards
h2 ESMO Calls for Urgent Action at Both EU and National Levels to Safeguard the Future of Oncological Research in Europe
h2 ESMO Journals Have Maintained Strong Impact Factors
h2 New ESMO President 2027-2028 Elected
h2 Three Prominent ESMO Officers Shine in News Pages for Their Accomplishments in Cancer Research
h2 Medical Oncologists Incredulous at the Commission’s Latest Backtracking on the Evaluation of the EU Tobacco Products Directive
h2 Education
h2 Provide your patients with the best care options.
h2 ESMO Courses
h2 ESMO Oncology Journals
h2 Publications
h2 Next Meetings
h2 ESMO Advanced Course on ADC Development, Therapeutic Applications and Research: Breast, Gynaecological and GI Cancers 2024: Zurich
h2 ESMO Advanced Course on ADC Development, Therapeutic Applications and Research: Thoracic and GU Cancers 2024: Singapore
h2 ESMO Advanced Course on ADC Development, Therapeutic Applications and Research: Breast, Gynaecological and GI Cancers 2024: Singapore
h2 Molecular Analysis for Precision Oncology Congress 2024
h2 ESMO Advanced Course on Cholangiocarcinoma 2024: Madrid
h2 ESMO Advanced Course on PARP Inhibition: Therapeutic Applications in Oncology 2024: Barcelona
h2 16th European Multidisciplinary Congress on Urological Cancers EMUC 2024
h2 ESMO Preceptorship on Lung Cancer 2024: Paris
h2 ESMO Advanced Course on Breast Cancer: Filling the Gaps Following Progression on CDK4/6 in Hormone Receptor Positive HER2 Negative Advanced Breast Cancer 2024: Doha
h2 ESMO Advanced Course on Pancreatic Cancer: From Standard Treatment to Individualization 2024: Barcelona
h2 ESMO Advanced Course on ADC Development, Therapeutic Applications and Research: Thoracic and Genitourinary Cancers 2024: Zurich
h2 ESMO Preceptorship on Gastric Cancer 2024: Singapore
h2 Video Gallery
h2 ESMO Asia 2024 – Unveiling the programme highlights. Prof Hanneke van Laarhoven & Prof Nadia Harbeck
h2 MAP 2024: shaping the future of precision oncology
h2 ESMO Breast Cancer 2025: Invitation from Scientific Committee Co-Chairs
h2 ESMO Asia Congress 2024: multidisciplinary oncology in the Asian region
h2 Why you should attend ESMO Asia 2024 - Prof. Long & Prof. van Laarhoven
h2 Why young oncologists should attend ESMO Asia 2024 - Prof. Lim
h2 ESMO Immuno-Oncology 2024: Experts in different tumour types explain the importance of this congress
h2 World renowned experts on why you should attend MAP 2024
h2 Why you should attend ESMO Asia 2024 - Prof. Cervantes
h2 ESMO Immuno-Oncology 2024 Congress Experts in the field invite you to share your research.
h2 ESMO 2024: Join your international community in Barcelona, or Online
h2 ESMO Recommendations on clinical reporting of genomics test results for solid cancers
h2 Career Development
h2 Improve your career path
h2 Are you looking for a fellowship not offered by ESMO or would like to post a fellowship?
h2 ESMO Examination
h2 Thinking of applying for an ESMO Oncology Fellowship?
h3 Membership
h2 Become a Member
h4 177
h4 40k +
h4 40+
h5 Legal
h5 Useful links
h5 Subscribe to ESMO newsletters

Comment résoudre les problèmes avec esmo.org

Les erreurs sur le site Web esmo.org peuvent être soit du côté serveur, soit de votre côté (côté client). S'il n'y a pratiquement rien à faire concernant les erreurs côté serveur (il ne reste plus qu'à attendre pour que le site fonctionne à nouveau), alors avec des erreurs côté client, il est possible de résoudre le problème de disponibilité de esmo.org par vous-même.